Post hoc analysis of the efficacy and safety of desvenlafaxine 50 mg/day in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder
Kornstein, Susan G., Clayton, Anita, Bao, Weihang, Guico-Pabia, Christine J.Volume:
21
Langue:
english
Journal:
Menopause
DOI:
10.1097/GME.0000000000000178
Date:
August, 2014
Fichier:
PDF, 292 KB
english, 2014